Market Closed -
Other stock markets
|
After market 01:06:17 pm | |||
124.6 EUR | +0.81% | 124.5 | -0.04% |
Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.39 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.46 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+57.86% | 25.12B | A | ||
-3.45% | 87.17B | A- | ||
+2.76% | 40.1B | A- | ||
-16.16% | 31.38B | B- | ||
-15.75% | 15.59B | C | ||
-9.12% | 12B | D+ | ||
-42.56% | 11.8B | B | ||
-17.46% | 11.8B | B- | ||
+6.89% | 8.81B | B+ | ||
-10.53% | 8.24B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UCB Stock
- Ratings UCB